PMID- 19347827
OWN - NLM
STAT- MEDLINE
DCOM- 20090430
LR  - 20141120
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 117
IP  - 1
DP  - 2009 Feb 25
TI  - Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer.
PG  - 32-9
LID - 10.1002/cncy.20008 [doi]
AB  - BACKGROUND: With the widespread development of genomic analysis, an accurate and 
      quick method for obtaining high-quality nucleic acids is needed. The objective of 
      the current study was to evaluate the quality and potential use of material 
      obtained from fine-needle aspiration cytology (FNAC). METHODS: Ultrasound- or 
      palpation-guided FNAC was performed in 124 consecutive patients who had nodular 
      breast lesions. The authors evaluated the amount of messenger RNA (mRNA) 
      obtained, its quality through the RNA Integrity (RIN) score, and the factors that 
      influenced both. For malignant lesions, the authors attempted to correlate 
      estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by 
      real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 
      detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ 
      hybridization (FISH) on the surgical specimen. RESULTS: The amount of mRNA 
      obtained was >1 microg in 89.5% of 124 samples (43 benign lesions and 81 
      adenocarcinomas). Overall, 59.3% of samples yielded >1 microg RNA with a RIN 
      score >6. The most significant predictors of quality and quantity of mRNA were 
      the cytopathologist who sampled the tumors and a diagnosis of cancer versus 
      benign lesion. The median ESR1 expression level, which was expressed as the 
      polymerase chain reaction cycle threshold (CT) level minus the average 18S value 
      (dct), was 17.7 dct in patients with estrogen receptor-negative tumors and 11.1 
      dct in patients with estrogen receptor-positive tumors. The median HER-2 
      expression level was 15.1 dct in patients with HER-2-negative tumors and 10.7 dct 
      in patients with HER-2-positive tumors. mRNA expression was concordant with the 
      IHC/FISH evaluation in 90.3% of patients for estrogen receptor status and in 
      98.5% of patients for HER-2 status. CONCLUSIONS: In 70% of cases, FNAC of breast 
      lesions in well trained hands allowed the extraction of mRNA suitable for gene 
      expression analysis.
CI  - (c) 2009 American Cancer Society.
FAU - Uzan, Catherine
AU  - Uzan C
AD  - Research Translational Laboratory, Histocytopathology Unit, Gustave Roussy 
      Institute, 39 rue Camille Desmoulins, Villejuif, France. catherine.uzan@igr.fr
FAU - Andre, Fabrice
AU  - Andre F
FAU - Scott, Veronique
AU  - Scott V
FAU - Laurent, Isabelle
AU  - Laurent I
FAU - Azria, Elie
AU  - Azria E
FAU - Suciu, Voichita
AU  - Suciu V
FAU - Balleyguier, Corinne
AU  - Balleyguier C
FAU - Lacroix, Ludovic
AU  - Lacroix L
FAU - Delaloge, Suzette
AU  - Delaloge S
FAU - Vielh, Philippe
AU  - Vielh P
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma/*diagnosis/genetics/surgery
MH  - *Biopsy, Fine-Needle
MH  - Breast Neoplasms/*diagnosis/genetics/surgery
MH  - Estrogen Receptor alpha/biosynthesis/genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - RNA, Messenger/*isolation & purification
MH  - Receptor, ErbB-2/biosynthesis/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2009/04/07 09:00
MHDA- 2009/05/01 09:00
CRDT- 2009/04/07 09:00
PHST- 2009/04/07 09:00 [entrez]
PHST- 2009/04/07 09:00 [pubmed]
PHST- 2009/05/01 09:00 [medline]
AID - 10.1002/cncy.20008 [doi]
PST - ppublish
SO  - Cancer. 2009 Feb 25;117(1):32-9. doi: 10.1002/cncy.20008.